INV4
3月前
Firefly partners with U.S. Defense Department on PTSD and TBI evaluation
March 26, 2026
Firefly Neuroscience, Inc. (NASDAQ:AIFF) said it has entered into a partnership with the U.S. Department of Defense to support the evaluation and treatment of active-duty service members and veterans affected by Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).
The small-cap company, which has a market capitalization of about $23.88 million, has seen its stock rise roughly 92% since the start of the year despite recent volatility, with shares recently trading around $1.68.
According to the company, the collaboration builds on work previously carried out by Evoke Neuroscience, Inc.—a firm Firefly acquired in May 2025—with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the Defense Department partnership were not disclosed.
Firefly’s FDA 510(k)-cleared AI-powered EEG/ERP platform is being used within related Defense Department initiatives. The technology provides quantitative neurological data to help military healthcare professionals with diagnosis, treatment planning and monitoring patient outcomes. The system is non-invasive and designed for use in both clinical and operational settings.
The company reported revenue growth of 958% over the twelve months ending in the third quarter of 2025, reaching $780,000, while maintaining a gross profit margin of 65.9%. Firefly currently holds more cash than debt on its balance sheet, though it remains unprofitable and continues to consume cash, reporting earnings per share of -$2.28.
The economic burden of PTSD in the United States has been estimated at $232.2 billion, with approximately $42.7 billion linked to the military population, according to research published in The Journal of Clinical Psychiatry in 2022. Data from the RAND Corporation indicates that more than 444,300 U.S. service members were diagnosed with at least one traumatic brain injury between 2000 and 2021.
“Every U.S. service member who comes home carrying the invisible wounds of PTSD and/or TBI deserves to be truly seen,” said Dave DeCaprio, President and Chief Operating Officer of Firefly.
Firefly maintains a proprietary dataset containing more than 191,000 EEG/ERP brain scans. The company develops AI-driven brain analytics tools designed to assist in evaluating neurological and mental health conditions including depression, dementia, anxiety disorders, concussions and ADHD.
Other recent developments
Firefly has also reported rapid expansion in its commercial partnerships. The company said its partner network increased twentyfold, while EEG/ERP brain scan volumes grew thirty-threefold.
By the end of 2025, Firefly had established 99 commercial partnerships and conducted more than 10,800 brain scans. The company said this represented growth of 1,880% in partner locations and a 3,227% increase in clinical assessments compared with the previous year.
The company also reported progress in research using its AI-based EEG/ERP technology aimed at distinguishing among the three main subtypes of attention-deficit/hyperactivity disorder (ADHD). Brain scans collected through its FDA-510(k)-cleared Evoke System are being used in research designed to identify biological differences between ADHD subtypes.
These developments, the company said, reflect its expanding role in the neurological and mental health diagnostics market.
Link article
$AIFF 🗞️
INV4
4月前
Firefly Confirms Public-Private Partnership with the Department of War
March 26, 2026
Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members
Partnership Represents a Significant Expansion of Company’s Commercial Footprint into the U.S. Government and Defense Health Sectors
KENMORE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (NASDAQ: AIFF) (“Firefly,” or the “Company”), today announced a partnership with the Department of War (“DoW”) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder (“PTSD”) and/or Traumatic Brain Injury (“TBI”).
The genesis of this innovative public-private brain health partnership was initial work by the founders of Evoke Neuroscience, Inc. (acquired by Firefly in May 2025) with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements.
Addressing a Multi-Billion Dollar Military Mental Health Crisis
PTSD and TBI represent two of the most significant and pervasive health challenges facing the U.S. military. The total excess economic burden of PTSD in the United States has been estimated at $232.2 billion, of which approximately $42.7 billion is attributed directly to the military population.1 In contrast to PTSD, the incidence of TBI is higher among military than civilian populations, in part because of the physical demands of military service and the potentially dangerous activities associated with military operations and training.2 According to the RAND Corporation, more than 444,300 U.S. service members were diagnosed with at least one TBI between 2000 and 2021.3
Despite the scale of this public and military health burden, objective, biomarker-driven diagnostic tools have remained largely absent from standard care — a gap that Firefly’s EEG/ERP technology is intended to help address.
FDA-Cleared AI Technology Supporting DoW Programs
Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP platform is being utilized across related DoW programs, providing military healthcare providers with objective, quantitative neurological data intended to support more precise diagnosis, individualized treatment planning, and measurable outcomes tracking. The platform is non-invasive, scalable across both clinical and operational environments, and designed for real-world deployment at scale. The DoW partnership represents a potentially significant channel for Firefly’s commercial strategy, expanding the Company’s footprint into the U.S. government and defense health sectors.
“Every U.S. service member who comes home carrying the invisible wounds of PTSD and/or TBI deserves to be truly seen — not just screened,” commented Dave DeCaprio, President and Chief Operating Officer of Firefly. “This partnership reflects our core mission: to bring the most advanced, objective brain health tools to the people who need them most, so that military healthcare providers may act earlier, treat more precisely, and give people a real path forward. We are proud that Firefly’s technology is being trusted to serve those who have sacrificed so much for this country.”
“We believe that this ongoing strategic partnership positions us well to benefit from the significant and growing U.S. government investment in military brain health — with a validated, FDA-cleared platform,” said Firefly’s Chief Executive Officer, Greg Lipschitz. “Our work with U.S. service members also complements our strategic initiative to build a proprietary foundation model of the human brain by combining a rapidly growing repository of brain scan data and important access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing.”
Sources
1 Davis LL, Schein J, Cloutier M, et al. “The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective.” The Journal of Clinical Psychiatry, 2022.
2 Haarbauer-Krupa J, et al “Epidemiology of Chronic Effects of Traumatic Brain Injury." J Neurotrauma, 2021.
3 RAND Corporation. “Improving Care for Veterans with Traumatic Brain Injury Across the Lifespan.” Commissioned by Wounded Warrior Project, 2022.
About Firefly Neuroscience
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
Link article
$AIFF 🗞️ 🤓
iHub News
4月前
Firefly partners with U.S. Defense Department on PTSD and TBI evaluationMarch 26, 2026 11:25 AM
IH Market News
Firefly Neuroscience, Inc. (NASDAQ:AIFF) said it has entered into a partnership with the U.S. Department of Defense to support the evaluation and treatment of active-duty service members and veterans affected by Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).The small-cap company, which has a market capitalization of about $23.88 million, has seen its stock rise roughly 92% since the start of the year despite recent volatility, with shares recently trading around $1.68.According to the company, the collaboration builds on work previously carried out by Evoke Neuroscience, Inc.—a firm Firefly acquired in May 2025—with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the Defense Department partnership were not disclosed.Firefly’s FDA 510(k)-cleared AI-powered EEG/ERP platform is being used within related Defense Department initiatives. The technology provides quantitative neurological data to help military healthcare professionals with diagnosis, treatment planning and monitoring patient outcomes. The system is non-invasive and designed for use in both clinical and operational settings.The company reported revenue growth of 958% over the twelve months ending in the third quarter of 2025, reaching $780,000, while maintaining a gross profit margin of 65.9%. Firefly currently holds more cash than debt on its balance sheet, though it remains unprofitable and continues to consume cash, reporting earnings per share of -$2.28.The economic burden of PTSD in the United States has been estimated at $232.2 billion, with approximately $42.7 billion linked to the military population, according to research published in The Journal of Clinical Psychiatry in 2022. Data from the RAND Corporation indicates that more than 444,300 U.S. service members were diagnosed with at least one traumatic brain injury between 2000 and 2021.“Every U.S. service member who comes home carrying the invisible wounds of PTSD and/or TBI deserves to be truly seen,” said Dave DeCaprio, President and Chief Operating Officer of Firefly.Firefly maintains a proprietary dataset containing more than 191,000 EEG/ERP brain scans. The company develops AI-driven brain analytics tools designed to assist in evaluating neurological and mental health conditions including depression, dementia, anxiety disorders, concussions and ADHD.
Other recent developments
Firefly has also reported rapid expansion in its commercial partnerships. The company said its partner network increased twentyfold, while EEG/ERP brain scan volumes grew thirty-threefold.By the end of 2025, Firefly had established 99 commercial partnerships and conducted more than 10,800 brain scans. The company said this represented growth of 1,880% in partner locations and a 3,227% increase in clinical assessments compared with the previous year.The company also reported progress in research using its AI-based EEG/ERP technology aimed at distinguishing among the three main subtypes of attention-deficit/hyperactivity disorder (ADHD). Brain scans collected through its FDA-510(k)-cleared Evoke System are being used in research designed to identify biological differences between ADHD subtypes.These developments, the company said, reflect its expanding role in the neurological and mental health diagnostics market.Firefly Neuroscience stock price
Original: Firefly partners with U.S. Defense Department on PTSD and TBI evaluation
INV4
4月前
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
March 13, 2026
Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research using Resting EEG/Cognitive EEG (ERP) brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder (“ADHD”): hyperactive and impulsive, inattentive, and combined.2 ADHD represents a U.S. treatment market estimated at over $10 billion, yet the condition has historically been diagnosed without objective biological tools for subtype differentiation.3
Today, a diagnosis of adult ADHD is based upon meeting the following general symptoms-based criteria: symptoms should be present in two or more settings, such as home, work or school; symptoms should clearly interfere with or reduce the functioning of a person in social, work, or school-related activities; symptoms experienced cannot be better explained by another mental health condition, such as depression or anxiety; and symptoms should not only occur during the course of a psychotic disorder like schizophrenia.4
In addition, healthcare professionals typically use the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) to distinguish between the three types of ADHD. According to the DSM-5, adult ADHD may be diagnosed in the following cases: (i) hyperactive and impulsive type ADHD - at least five symptoms of hyperactivity and impulsivity for more than six months without meeting the diagnostic criteria for inattentive behavior; (ii) inattentive type ADHD - at least five symptoms of inattention for more than six months without meeting the diagnostic criteria for hyperactive or impulsive behavior; and (iii), combined type ADHD - at least five symptoms of hyperactivity and impulsivity and at least five symptoms of inattention for more than 6 months.4
Gil Issachar, Chief Technology Officer of Firefly, commented, “While there has been significant progress made in the treatment of ADHD over the years, there is no question that significant unmet need remains, particularly after a general diagnosis of the disorder has been made. For example, some types of ADHD respond well to stimulants, while others don’t and neurofeedback therapy may be recommended instead.5 Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans. We believe that the technology also opens the door to ongoing treatment monitoring — allowing clinicians to objectively track whether an intervention is working at the neurological level.”
Firefly’s methodology is supported by prior peer-reviewed research, including a study published in Frontiers in Psychiatry, demonstrating the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients.6
Greg Lipschitz, Chief Executive Officer of Firefly, said, “This latest Firefly cognitive brain biomarker discovery serves as another demonstration of how we are harnessing the power of AI and EEG/ERP to potentially transform neuroscience and clinical development. Moving forward, armed with a growing foundation of brain scan data and important access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing, we believe that we are on the right path to making even more breakthroughs in cognitive brain biomarker discovery, as well as to fulfilling our goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
Sources
1 https://chadd.org/about-adhd/general-prevalence/
2 https://doi.org/10.1017/S0033291716003329
3 https://www.grandviewresearch.com/industry-analysis/us-attention-deficit-hyperactivity-disorder-market-report
4 https://add.org/adhd-types/
5 https://www.nature.com/articles/d41586-026-00095-w
6 https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1026616/full
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Link article
$AIFF 🗞️
INV4
4月前
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
March 5, 2026
GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions
NEW YORK, March 5, 2026 /PRNewswire/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially for people who may not have nearby providers or prefer remote care. Active Companies in the biotech space of interest include: Helus PharmaTM (NASDAQ: HELP) (Cboe CA: HELP), Acadia Healthcare Company, Inc. (NASDAQ: ACHC), Johnson & Johnson (NYSE: JNJ), BrainsWay Ltd. (NASDAQ: BWAY), Firefly Neuroscience, Inc. (NASDAQ: AIFF).
The market for anxiety treatments is growing as awareness of mental health increases and more people seek help. Industry estimates suggest the global market for GAD treatments was around $1.8 billion in 2023 and could grow to more than $4.26 billion by 2033, representing roughly 9% annual growth. This growth reflects rising demand for both traditional therapies and newer digital solutions that allow patients to receive care in more flexible and personalized ways. Experts also expect the broader anxiety treatment market to reach well over $12 billion to $17+ billion in the next decade as mental health care continues to expand.
Looking ahead, innovation in GAD therapies and investment in mental health solutions are likely to keep the market moving upward. New medications, improved psychotherapy techniques, and technology-driven tools are giving patients more options than ever before. As mental health care becomes more integrated into mainstream healthcare systems, companies and investors focused on this space may benefit from long-term growth while helping address one of the most common mental health conditions in the world.
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Link article
$AIFF 🗞️
iHub News
4月前
Firefly Neuroscience stock jumps 80% as company advances AI-based brain modelMarch 4, 2026 10:58 AM
IH Market News
Firefly Neuroscience, Inc. (NASDAQ:AIFF) shares surged about 80% after the company reported progress in developing what it describes as the world’s first EEG/ERP-based foundation model of the human brain, supported by NVIDIA GPU acceleration.The company said its commercial footprint expanded more than twentyfold during 2025, while the volume of EEG/ERP brain scans processed increased 33 times year over year. Following its acquisition of Evoke Neuroscience Inc. and additional internal growth initiatives, Firefly ended the year with 99 commercial partners that collectively completed more than 10,800 EEG/ERP brain scans.Growth in partner sites and clinical assessments reached 1,880% and 3,227%, respectively, according to the company.“Our mission is to harness the power of AI and EEG/ERP to transform neuroscience and clinical development,” said Greg Lipschitz, Chief Executive Officer. “With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”Firefly’s proprietary database now contains more than 191,000 EEG/ERP brain scans, which the company says represents the largest standardized repository of its kind. Its FDA-cleared brain analytics technology is intended to improve diagnostic and treatment monitoring capabilities for neurological and psychiatric conditions such as depression, dementia, anxiety disorders, concussions and ADHD.The company said the latest developments represent an important step toward the eventual commercial launch of its brain foundation model, which aims to provide clinicians and researchers with deeper insights into brain function.Over the past year, AIFF shares have traded between $0.62 and $6.00. The stock was recently trading around $1.23, reflecting an approximately 80% gain on the day.Firefly Neuroscience stock price
Original: Firefly Neuroscience stock jumps 80% as company advances AI-based brain model
INV4
4月前
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
March 4, 2026
Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.
Through its acquisition of Evoke Neuroscience, Inc. and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans.
The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.
“As demonstrated by this significant expansion of our commercial footprint and meaningful increase in our brain scan volumes, we continue to successfully execute against the key pillars of our growth strategy,” said Greg Lipschitz, Firefly’s Chief Executive Officer. “Our mission is to harness the power of AI and EEG/ERP to transform neuroscience and clinical development. With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the Company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
https://investorshub.advfn.com/stock-market/NASDAQ/firefly-neuroscience-AIFF/stock-news/97976257/firefly-progresses-toward-development-and-commerci
=================
AIFF Institutional Holdings
Ownership Summary
Institutional Ownership 6.43%
Total Shares Outstanding (millions) 14
Total Value of Holdings (millions) $1
https://www.nasdaq.com/market-activity/stocks/aiff/institutional-holdings
$AIFF
georgie18
12月前
AIFF...$3.12..🥳...I thnk we will see a major run here...
georgie18
Member Level
Re: georgie18 post# 121
Monday, July 21, 2025 10:11:46 AM
Post#
122
of 122
AIFF...$3.09...🥳...Getting some traction here...
georgie18
Member Level
Re: georgie18 post# 689906
Thursday, July 17, 2025 11:33:29 AM
Post#
689921
of 690408
AIFF...$3.05...🥳...Nice Blocks being bought here...Accumulation under way...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 119
Thursday, July 17, 2025 10:36:21 AM
Post#
120
of 120
AIFF...$3.03...🥳...Hod...Confirmation Candle on the Bullish Morning Star Reversal Pattern on yesterdays close...
georgie18
Member Level
Re: georgie18 post# 689645
Wednesday, July 16, 2025 2:16:56 PM
Post#
689710
of 689905
AIFF...$2.94...🥳...Hod...Zero Borrow...
georgie18
Member Level
Re: georgie18 post# 117
Wednesday, July 16, 2025 11:54:57 AM
Post#
118
of 118
AIFF...$2.85...🥳...Reversal Candle setting up here off the bottom...
georgie18
Member Level
Re: georgie18 post# 689356
Wednesday, July 16, 2025 8:39:15 AM
Post#
689551
of 689644
AIFF...$2.75...🥳...Zero Borrow...Dipped to $2.53 this morning...
georgie18
Member Level
Re: georgie18 post# 115
Tuesday, July 15, 2025 8:03:05 AM
Post#
116
of 116
AIFF...$2.80...🥳...Added here...
georgie18
Member Level
Re: georgie18 post# 689237
Monday, July 14, 2025 11:38:10 AM
Post#
689274
of 689355
AIFF...🥳...Good load opportunity under $3...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 113
Monday, July 14, 2025 9:21:51 AM
Post#
114
of 114
AIFF...🥳...$3.08 On the dip...Hit $4 plus this morning...
georgie18
Member Level
Re: georgie18 post# 689045
Monday, July 14, 2025 8:01:17 AM
Post#
689200
of 689235
AIFF...$3.88...🥳...Off my $3.04 Alert...https://finviz.com/news/102512/firefly-inks-latest-commercial-agreement-for-use-of-its-fda-cleared-bna-platform-in-groundbreaking-precision-neuroscience-research
georgie18
Member Level
Re: None
Friday, July 11, 2025 9:56:54 AM
Post#
112
of 112
AIFF...$3.04...🥳...66K Bidder at $3.00
georgie18
12月前
AIFF...$3.09...🥳...Getting some traction here...
georgie18
Member Level
Re: georgie18 post# 689906
Thursday, July 17, 2025 11:33:29 AM
Post#
689921
of 690408
AIFF...$3.05...🥳...Nice Blocks being bought here...Accumulation under way...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 119
Thursday, July 17, 2025 10:36:21 AM
Post#
120
of 120
AIFF...$3.03...🥳...Hod...Confirmation Candle on the Bullish Morning Star Reversal Pattern on yesterdays close...
georgie18
Member Level
Re: georgie18 post# 689645
Wednesday, July 16, 2025 2:16:56 PM
Post#
689710
of 689905
AIFF...$2.94...🥳...Hod...Zero Borrow...
georgie18
Member Level
Re: georgie18 post# 117
Wednesday, July 16, 2025 11:54:57 AM
Post#
118
of 118
AIFF...$2.85...🥳...Reversal Candle setting up here off the bottom...
georgie18
Member Level
Re: georgie18 post# 689356
Wednesday, July 16, 2025 8:39:15 AM
Post#
689551
of 689644
AIFF...$2.75...🥳...Zero Borrow...Dipped to $2.53 this morning...
georgie18
Member Level
Re: georgie18 post# 115
Tuesday, July 15, 2025 8:03:05 AM
Post#
116
of 116
AIFF...$2.80...🥳...Added here...
georgie18
Member Level
Re: georgie18 post# 689237
Monday, July 14, 2025 11:38:10 AM
Post#
689274
of 689355
AIFF...🥳...Good load opportunity under $3...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 113
Monday, July 14, 2025 9:21:51 AM
Post#
114
of 114
AIFF...🥳...$3.08 On the dip...Hit $4 plus this morning...
georgie18
Member Level
Re: georgie18 post# 689045
Monday, July 14, 2025 8:01:17 AM
Post#
689200
of 689235
AIFF...$3.88...🥳...Off my $3.04 Alert...https://finviz.com/news/102512/firefly-inks-latest-commercial-agreement-for-use-of-its-fda-cleared-bna-platform-in-groundbreaking-precision-neuroscience-research
georgie18
Member Level
Re: None
Friday, July 11, 2025 9:56:54 AM
Post#
112
of 112
AIFF...$3.04...🥳...66K Bidder at $3.00
georgie18
12月前
AIFF...$3.05...🥳...Nice Blocks being bought here...Accumulation under way...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 119
Thursday, July 17, 2025 10:36:21 AM
Post#
120
of 120
AIFF...$3.03...🥳...Hod...Confirmation Candle on the Bullish Morning Star Reversal Pattern on yesterdays close...
georgie18
Member Level
Re: georgie18 post# 689645
Wednesday, July 16, 2025 2:16:56 PM
Post#
689710
of 689905
AIFF...$2.94...🥳...Hod...Zero Borrow...
georgie18
Member Level
Re: georgie18 post# 117
Wednesday, July 16, 2025 11:54:57 AM
Post#
118
of 118
AIFF...$2.85...🥳...Reversal Candle setting up here off the bottom...
georgie18
Member Level
Re: georgie18 post# 689356
Wednesday, July 16, 2025 8:39:15 AM
Post#
689551
of 689644
AIFF...$2.75...🥳...Zero Borrow...Dipped to $2.53 this morning...
georgie18
Member Level
Re: georgie18 post# 115
Tuesday, July 15, 2025 8:03:05 AM
Post#
116
of 116
AIFF...$2.80...🥳...Added here...
georgie18
Member Level
Re: georgie18 post# 689237
Monday, July 14, 2025 11:38:10 AM
Post#
689274
of 689355
AIFF...🥳...Good load opportunity under $3...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 113
Monday, July 14, 2025 9:21:51 AM
Post#
114
of 114
AIFF...🥳...$3.08 On the dip...Hit $4 plus this morning...
georgie18
Member Level
Re: georgie18 post# 689045
Monday, July 14, 2025 8:01:17 AM
Post#
689200
of 689235
AIFF...$3.88...🥳...Off my $3.04 Alert...https://finviz.com/news/102512/firefly-inks-latest-commercial-agreement-for-use-of-its-fda-cleared-bna-platform-in-groundbreaking-precision-neuroscience-research
georgie18
Member Level
Re: None
Friday, July 11, 2025 9:56:54 AM
Post#
112
of 112
AIFF...$3.04...🥳...66K Bidder at $3.00
georgie18
12月前
AIFF...$3.03...🥳...Hod...Confirmation Candle on the Bullish Morning Star Reversal Pattern on yesterdays close...
georgie18
Member Level
Re: georgie18 post# 689645
Wednesday, July 16, 2025 2:16:56 PM
Post#
689710
of 689905
AIFF...$2.94...🥳...Hod...Zero Borrow...
georgie18
Member Level
Re: georgie18 post# 117
Wednesday, July 16, 2025 11:54:57 AM
Post#
118
of 118
AIFF...$2.85...🥳...Reversal Candle setting up here off the bottom...
georgie18
Member Level
Re: georgie18 post# 689356
Wednesday, July 16, 2025 8:39:15 AM
Post#
689551
of 689644
AIFF...$2.75...🥳...Zero Borrow...Dipped to $2.53 this morning...
georgie18
Member Level
Re: georgie18 post# 115
Tuesday, July 15, 2025 8:03:05 AM
Post#
116
of 116
AIFF...$2.80...🥳...Added here...
georgie18
Member Level
Re: georgie18 post# 689237
Monday, July 14, 2025 11:38:10 AM
Post#
689274
of 689355
AIFF...🥳...Good load opportunity under $3...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 113
Monday, July 14, 2025 9:21:51 AM
Post#
114
of 114
AIFF...🥳...$3.08 On the dip...Hit $4 plus this morning...
georgie18
Member Level
Re: georgie18 post# 689045
Monday, July 14, 2025 8:01:17 AM
Post#
689200
of 689235
AIFF...$3.88...🥳...Off my $3.04 Alert...https://finviz.com/news/102512/firefly-inks-latest-commercial-agreement-for-use-of-its-fda-cleared-bna-platform-in-groundbreaking-precision-neuroscience-research
georgie18
Member Level
Re: None
Friday, July 11, 2025 9:56:54 AM
Post#
112
of 112
AIFF...$3.04...🥳...66K Bidder at $3.00
georgie18
12月前
AIFF...$2.94...🥳...Hod...Zero Borrow...
georgie18
Member Level
Re: georgie18 post# 117
Wednesday, July 16, 2025 11:54:57 AM
Post#
118
of 118
AIFF...$2.85...🥳...Reversal Candle setting up here off the bottom...
georgie18
Member Level
Re: georgie18 post# 689356
Wednesday, July 16, 2025 8:39:15 AM
Post#
689551
of 689644
AIFF...$2.75...🥳...Zero Borrow...Dipped to $2.53 this morning...
georgie18
Member Level
Re: georgie18 post# 115
Tuesday, July 15, 2025 8:03:05 AM
Post#
116
of 116
AIFF...$2.80...🥳...Added here...
georgie18
Member Level
Re: georgie18 post# 689237
Monday, July 14, 2025 11:38:10 AM
Post#
689274
of 689355
AIFF...🥳...Good load opportunity under $3...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 113
Monday, July 14, 2025 9:21:51 AM
Post#
114
of 114
AIFF...🥳...$3.08 On the dip...Hit $4 plus this morning...
georgie18
Member Level
Re: georgie18 post# 689045
Monday, July 14, 2025 8:01:17 AM
Post#
689200
of 689235
AIFF...$3.88...🥳...Off my $3.04 Alert...https://finviz.com/news/102512/firefly-inks-latest-commercial-agreement-for-use-of-its-fda-cleared-bna-platform-in-groundbreaking-precision-neuroscience-research
georgie18
Member Level
Re: None
Friday, July 11, 2025 9:56:54 AM
Post#
112
of 112
AIFF...$3.04...🥳...66K Bidder at $3.00
georgie18
1年前
AIFF...$3.21...🥳... https://schrts.co/NBwuuWpf ...Looking for Channel Breakout...
georgie18
Member Level
Re: georgie18 post# 394883
Wednesday, July 02, 2025 3:53:09 PM
Post#
395023
of 395040
AIFF...$3.11...🥳
georgie18
Member Level
Re: georgie18 post# 106
Friday, June 27, 2025 10:06:37 AM
Post#
107
of 108
AIFF...$3.02...🥳...Hit $17 just 6 months ago....Break/Hold $3.16 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 394666
Monday, June 23, 2025 9:52:45 AM
Post#
394670
of 394882
AIFF...10,000 Share Buy at $2.80...🥳...Added the dip...
georgie18
Member Level
Re: georgie18 post# 104
Monday, June 23, 2025 7:54:03 AM
Post#
105
of 105
AIFF...$2.72...🥳...Here's a piece of Friday's News...Greg Lipschitz, CEO of Firefly, said, “It is important to note that this was not a lab study. It utilized patients in memory clinics (161 for EEG, 111 for MRI), so it was real-world data. The research supports the use of office based electrophysiology and imaging to reliably spot who was starting to decline, and who had dementia — with nearly the same accuracy as more invasive and costly tests. The bottom line is that combining our BNA™ technology with vMRI imaging is faster, easier, and can be done in more places.”
georgie18
Member Level
Re: georgie18 post# 393131
Friday, June 20, 2025 7:58:00 AM
Post#
394572
of 394666
AIFF...$3.64...🥳...Off my $2.90 Alert...https://finviz.com/news/84468/firefly-neuroscience-researchers-uncover-powerful-new-way-of-objectively-measuring-scd-mci-and-dementia-in-alzheimers-patients
georgie18
Member Level
Re: None
Wednesday, May 07, 2025 9:49:06 AM
Post#
103
of 104
AIFF...Back in in the $2.90s...🥳
georgie18
1年前
AIFF...$3.11...🥳
georgie18
Member Level
Re: georgie18 post# 106
Friday, June 27, 2025 10:06:37 AM
Post#
107
of 108
AIFF...$3.02...🥳...Hit $17 just 6 months ago....Break/Hold $3.16 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 394666
Monday, June 23, 2025 9:52:45 AM
Post#
394670
of 394882
AIFF...10,000 Share Buy at $2.80...🥳...Added the dip...
georgie18
Member Level
Re: georgie18 post# 104
Monday, June 23, 2025 7:54:03 AM
Post#
105
of 105
AIFF...$2.72...🥳...Here's a piece of Friday's News...Greg Lipschitz, CEO of Firefly, said, “It is important to note that this was not a lab study. It utilized patients in memory clinics (161 for EEG, 111 for MRI), so it was real-world data. The research supports the use of office based electrophysiology and imaging to reliably spot who was starting to decline, and who had dementia — with nearly the same accuracy as more invasive and costly tests. The bottom line is that combining our BNA™ technology with vMRI imaging is faster, easier, and can be done in more places.”
georgie18
Member Level
Re: georgie18 post# 393131
Friday, June 20, 2025 7:58:00 AM
Post#
394572
of 394666
AIFF...$3.64...🥳...Off my $2.90 Alert...https://finviz.com/news/84468/firefly-neuroscience-researchers-uncover-powerful-new-way-of-objectively-measuring-scd-mci-and-dementia-in-alzheimers-patients
georgie18
Member Level
Re: None
Wednesday, May 07, 2025 9:49:06 AM
Post#
103
of 104
AIFF...Back in in the $2.90s...🥳
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
3月前
TrendTrade2016
4月前
BadCuda
4月前
Zardiw
4月前
ErnieBilco
9月前
メールアドレスで登録
